We are pursuing this expansive field with speed, scale and intention. Proteovant integrates its foundational degrader portfolio, extensive internal drug hunting expertise, and VantAI’s proprietary ‘Protein Contact First’ deep learning platform to advance novel protein degraders across a range of therapeutic areas. The acquisition of Oncopia Therapeutics in 2020 provided access to sophisticated degrader design capabilities and a robust patented pipeline.
Additionally, we have the strong backing and life sciences expertise of our lead investor, Roivant Sciences.
Drew Fromkin
Chief Executive Officer
Ruby Holder, MBA
Chief Strategy Officer
Zhihua Sui, PhD
Chief Scientific Officer
Tiago Girão, CPA
Chief Financial Officer